Abbreviations
bid, twice a day; CRP, C-reactive protein; CT, computed tomography; ESR, erythrocyte
sedimentation rate; IDSA, Infectious Diseases Society of America; IV, intravenous; MRI,
magnetic resonance imaging ; NVO, native vertebral osteomyelitis; PO, by mouth; qid, four
times a day; tid, three times a day; IV, intravenous
Source
Elie F Berbari EF, Kanj Ss, Kowalski TJ, et al. 2015 Infectious Diseases Society of America
(IDSA) Clinical Practice Guideline for the Diagnosis and Treatment of Native Vertebral
Osteomyelitis (NVO) in Adults.
Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient care.
It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be
considered exclusive of other methods of care reasonably directed at obtaining the same results. e
ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer
consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated with
the distributor of this clinical reference tool.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2015 All rights reserved
IDSAVER15072
Table 3. Strength of Recommendation and Quality of Evidence
(cont'd)
Strength of
Recommendation/
Quality of Evidence
Clarity of Balance
Between Desirable and
Undesirable Effects
Methodological
Quality of Supporting
Evidence (examples) Implications
W/L
Uncertainty in the
estimates of Desirable
effects, harms, and
burden; Desirable
effects, harms, and
burden may be closely
balanced
Evidence for at least one
critical outcome from
observational studies,
from RCTs with
serious flaws or indirect
evidence
Other alternatives may
be equally reasonable
Further research is very
likely to have an important
impact on our confidence
in the estimate of effect
and is likely to change the
estimate.
W/VL
Major uncertainty
in the estimates of
desirable effects, harms,
and burden; Desirable
effects may or may
not be balanced with
undesirable effects
Evidence for at least one
critical outcome from
unsystematic clinical
observations or very
indirect evidence
Other alternatives may be
equally reasonable. Any
estimate of effect, for at
least one critical outcome, is
very uncertain.
Strength of Recommendation Quality of Evidence
S=strong H=high L=low
W=weak M=moderate VL=very low
